GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
GERON CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$1.20+0.03 (+2.56%)
Close on Oct 19, 2026
- Market cap
- $804.84K
- P/E (TTM)
- –
- Dividend yield
- –
GERON CORP revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Gross product revenue | $223.11M | $89.42M | – | – | 54.8% | +149.5% |
| Product revenue, net | $183.62M | $76.50M | $0 | $0 | 45.1% | +140.0% |
| Royalties | $258.00K | $499.00K | $237.00K | – | 0.1% | -48.3% |
| Government rebates | -$2.60M | -$926.00K | – | – | -0.6% | +181.1% |
| Sales returns and allowances | -$3.85M | -$225.00K | – | – | -0.9% | +1610.7% |
| Distributor service fees | -$7.51M | -$3.05M | – | – | -1.8% | +146.5% |
| Chargebacks | -$25.53M | -$8.72M | – | – | -6.3% | +192.6% |
| Total gross-to-net adjustments | -$39.49M | -$12.92M | – | – | -9.7% | +205.6% |
| License Fees and Royalties | – | $499.00K | $237.00K | $596.00K | – | – |
| Chargebacks and distributor service fees | – | -$11.77M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Geron's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.